Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.28 | N/A | +296.52% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.28 | N/A | +296.52% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to growth. However, they did not provide specific guidance for the upcoming quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on strategic growth and innovation.
Ligand Pharmaceuticals reported a strong earnings per share figure, significantly exceeding expectations, which contributed to a 1.7% increase in stock price. The company did not disclose revenue figures or future guidance, leaving some uncertainty for investors. Overall, the positive EPS surprise indicates strong operational performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STRYKER CORP
May 1, 2023